Millipore Sigma Vibrant Logo

204873 Complement C1, Human

Complement C1, Human Native, is the first component of the classical complement pathway. It is a calcium-dependent complex of C1q, C1r, and C1s subcomponents.

Complement C1, Human: のSDS（安全データシート）、CoA（試験成績書）およびCoQ（品質証明書）、カタログなど製品関連の技術資料を入手いただけます。
View This Product on Sigma-Aldrich
204873
価格＆在庫状況を照会

概要

Replacement Information

価格＆在庫状況

カタログ番号 在庫状況包装 Qty/Pk 価格 数量
204873-200UGCN
在庫状況検索中…
—
現在国内在庫なし 現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

      		 樹脂ｱﾝﾌﾟﾙ 200 μg
      価格を検索中…
      価格が見つかりません
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      弊社照会 詳細を表示　
      値引
      ()
       
      —
      弊社照会
      		 —
      Description
      OverviewNative, human C1 complement component. C1 is the first component of the classical complement pathway. It is a calcium-dependent complex of C1q, C1r, and C1s subcomponents which are present in the C1 complex at molar ratios of 1:2:2, respectively. Binding of C1 to classical pathway activators results in the conversion of the proenzyme C1s subcomponent to an active C1s enzyme. C1s enzyme cleaves both C4 and C2 resulting in formation of the C3 cleaving enzyme, C4b, C2a, of the classical complement pathway. C1 concentration is based on functional activity measurements relative to a normal serum standard pool.
      Catalogue Number204873
      Brand Family Calbiochem®
      References
      ReferencesCooper, N.R. 1985. Adv. Immunol. 37, 151.
      Ziccardi, R.J. and Cooper, N.R. 1977. J. Immunol. 118, 2047.
      Product Information
      FormLiquid
      FormulationIn 300 mM NaCl, 50 mM sodium acetate, 50 mM EACA, 25 µM NPGB, 10 mM benzamidine, 10 mM EDTA, 40% glycerol, pH 5.5.
      Quality LevelMQ100
      Applications
      Biological Information
      SourcePrepared from plasma of individuals that have been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage ≤ -70°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      カタログ番号 GTIN
      204873-200UGCN 04055977219678

      Documentation

      Complement C1, Human (M)SDS

      タイトル

      英語版製品安全データシート（(M)SDS） 

      Complement C1, Human 試験成績書（CoA）

      タイトルロット番号
      204873

      参考資料

      参考資料の概要
      Cooper, N.R. 1985. Adv. Immunol. 37, 151.
      Ziccardi, R.J. and Cooper, N.R. 1977. J. Immunol. 118, 2047.
      データシート

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision27-May-2008 RFH
      DescriptionNative, human C1 complement component. C1 is the first component of the classical complement pathway. It is a calcium dependent complex of C1q, C1r, and C1s subcomponents which are present in the C1 complex at molar ratios of 1:2:2 respectively. Binding of C1 to classical pathway activators results in the conversion of the proenzyme C1s subcomponent to an active C1s enzyme. C1s enzyme cleaves both C4 and C2, resulting in formation of the C3 cleaving enzyme, C4b, C2a, of the classical complement pathway. C1 concentration is based on functional activity measurements relative to a normal serum standard pool.
      FormLiquid
      FormulationIn 300 mM NaCl, 50 mM sodium acetate, 50 mM EACA, 25 µM NPGB, 10 mM benzamidine, 10 mM EDTA, 40% glycerol, pH 5.5.
      Concentration Label Please refer to vial label for lot-specific concentration
      SourcePrepared from plasma of individuals that have been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
      Storage Avoid freeze/thaw
      ≤ -70°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Toxicity Standard Handling
      ReferencesCooper, N.R. 1985. Adv. Immunol. 37, 151.
      Ziccardi, R.J. and Cooper, N.R. 1977. J. Immunol. 118, 2047.